Background Only clinically validated HPV assays can be accepted in cervical cancer
screening. Objectives To update the list of high-risk HPV assays that fulfil the 2009 …

Introduction The WHO recommends human papillomavirus (HPV) cervical self-sampling as
an additional screening method and HPV DNA testing as an effective approach for the early …

Cervical cancer is one of the leading causes of cancer death among females worldwide and
its behavior epidemiologically likes a venereal disease of low infectiousness. Early age at …

Background Cervical screening and human papillomavirus (HPV) vaccination have been
implemented in most high-income countries; however, coverage is low in low-income and …

Objective To evaluate the diagnostic accuracy of high-risk human papillomavirus (hrHPV)
assays on self samples and the efficacy of self sampling strategies to reach underscreened …

Background Cervical cancer screening tests that identify DNA of the main causal agent, high-
risk human papillomavirus (HPV) types, are more protective than cervical cytology. We …

Background Human papillomavirus (HPV) testing on self-samples represents a great
opportunity to increase cervical cancer screening uptake among under-screened women …

Despite HPV vaccines, screening will remain central for decades to control cervical cancer.
Recently, HPV testing alone or with cytology was introduced as an alternative to cytology …

Infection of cervical epithelium with high-risk human papilloma virus (hrHPV) might result in
productive or transforming cervical intraepithelial neoplasia (CIN) lesions, the morphology of …

Introduction Population coverage for cervical cancer screening is an important determinant
explaining differences in the incidence of cervical cancer between countries. Offering …